<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid>9748909</pmcid><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">36517767</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmc">9748909</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">1526</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1186/s10194-022-01526-5</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Research Visits and Activities. Only those participants who continue to meet eligibility criteria after the run-in phase participated in the subsequent research visits. QST = quantitative sensory testing; MRI = magnetic resonance imaging</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1"><label>Table 1</label><caption><p>Research Visits and Activities. Only those participants who continue to meet eligibility criteria after the run-in phase participated in the subsequent research visits. QST = quantitative sensory testing; MRI = magnetic resonance imaging</p></caption><graphic position="anchor" xlink:href="10194_2022_1526_Tab1_HTML" id="MO1"/></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Research Visits and Activities. Only those participants who continue to meet eligibility criteria after the run-in phase participated in the subsequent research visits. QST = quantitative sensory testing; MRI = magnetic resonance imaging</div><div xmlns="http://www.w3.org/1999/xhtml"><a id="MO1"/><img src=""/></div></transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Regions of Interest. The 63 a priori-selected ROIs and their MNI coordinates are shown. For thirty-one of the ROIs, a right-hemisphere and a left-hemisphere ROI was included. Only a midline ROI for periaqueductal gray was included. Each ROI was an 8 mm diameter sphere</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2"><label>Table 2</label><caption><p>Regions of Interest. The 63 a priori-selected ROIs and their MNI coordinates are shown. For thirty-one of the ROIs, a right-hemisphere and a left-hemisphere ROI was included. Only a midline ROI for periaqueductal gray was included. Each ROI was an 8 mm diameter sphere</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Region Name</th><th colspan="3">MNI Coordinates (X, Y, Z)</th></tr><tr><th>Anterior Insula</th><th>+/−  38</th><th>19</th><th>−3</th></tr></thead><tbody><tr><td>Anterior Cingulate</td><td>+/− 6</td><td>28</td><td>24</td></tr><tr><td>Middle Cingulate</td><td>+/− 10</td><td>−7</td><td>46</td></tr><tr><td>Posterior Cingulate</td><td>+/− 8</td><td>− 48</td><td>39</td></tr><tr><td>Posterior Insula</td><td>+/− 40</td><td>− 14</td><td>1</td></tr><tr><td>Thalamus</td><td>+/− 8</td><td>− 21</td><td>7</td></tr><tr><td>Primary Somatosensory</td><td>+/− 46</td><td>−24</td><td>47</td></tr><tr><td>Dorsolateral Prefrontal</td><td>+/− 40</td><td>39</td><td>24</td></tr><tr><td>Inferior Lateral Parietal</td><td>+/−  57</td><td>−48</td><td>30</td></tr><tr><td>Ventromedial Prefrontal</td><td>+/− 6</td><td>36</td><td>−14</td></tr><tr><td>Secondary Somatosensory</td><td>+/−  52</td><td>−28</td><td>21</td></tr><tr><td>Somatomotor</td><td>+/−  6</td><td>1</td><td>68</td></tr><tr><td>Temporal Pole</td><td>+/−  41</td><td>10</td><td>−32</td></tr><tr><td>Amygdala</td><td>+/−  22</td><td>−1</td><td>−22</td></tr><tr><td>Middle Temporal</td><td>+/−  60</td><td>−26</td><td>−5</td></tr><tr><td>Caudate</td><td>+/− 14</td><td>13</td><td>11</td></tr><tr><td>Middle Occipital</td><td>+/−  34</td><td>− 72</td><td>6</td></tr><tr><td>Cuneus</td><td>+/− 13</td><td>− 93</td><td>9</td></tr><tr><td>Hypothalamus</td><td>+/− 6</td><td>−6</td><td>−12</td></tr><tr><td>Lingual Gyrus</td><td>+/−  19</td><td>− 64</td><td>−11</td></tr><tr><td>Spinal Trigeminal Nucleus</td><td>+/− 6</td><td>− 39</td><td>− 45</td></tr><tr><td>Precuneus</td><td>+/−  6</td><td>− 58</td><td>46</td></tr><tr><td>Parieto-Occipital</td><td>+/−  51</td><td>−64</td><td>18</td></tr><tr><td>Supramarginal Gyrus</td><td>+/− 44</td><td>− 42</td><td>24</td></tr><tr><td>Precentral</td><td>+/− 44</td><td>−4</td><td>40</td></tr><tr><td>Middle Frontal</td><td>+/−  35</td><td>6</td><td>52</td></tr><tr><td>Pulvinar</td><td>+/− 20</td><td>−34</td><td>3</td></tr><tr><td>Fusiform Gyrus</td><td>+/− 51</td><td>− 59</td><td>−9</td></tr><tr><td>Superior Parietal</td><td>+/− 40</td><td>−52</td><td>− 49</td></tr><tr><td>Dorsal Pons</td><td>+/− 6</td><td>−36</td><td>−27</td></tr><tr><td>Cerebellum</td><td>+/− 46</td><td>− 53</td><td>−39</td></tr><tr><td>Periaqueductal Gray</td><td>−1</td><td>−26</td><td>−11</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Regions of Interest. The 63 a priori-selected ROIs and their MNI coordinates are shown. For thirty-one of the ROIs, a right-hemisphere and a left-hemisphere ROI was included. Only a midline ROI for periaqueductal gray was included. Each ROI was an 8 mm diameter sphere</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th>Region Name</th><th colspan="3">MNI Coordinates (X, Y, Z)</th></tr><tr><th>Anterior Insula</th><th>+/−  38</th><th>19</th><th>−3</th></tr></thead><tbody><tr><td>Anterior Cingulate</td><td>+/− 6</td><td>28</td><td>24</td></tr><tr><td>Middle Cingulate</td><td>+/− 10</td><td>−7</td><td>46</td></tr><tr><td>Posterior Cingulate</td><td>+/− 8</td><td>− 48</td><td>39</td></tr><tr><td>Posterior Insula</td><td>+/− 40</td><td>− 14</td><td>1</td></tr><tr><td>Thalamus</td><td>+/− 8</td><td>− 21</td><td>7</td></tr><tr><td>Primary Somatosensory</td><td>+/− 46</td><td>−24</td><td>47</td></tr><tr><td>Dorsolateral Prefrontal</td><td>+/− 40</td><td>39</td><td>24</td></tr><tr><td>Inferior Lateral Parietal</td><td>+/−  57</td><td>−48</td><td>30</td></tr><tr><td>Ventromedial Prefrontal</td><td>+/− 6</td><td>36</td><td>−14</td></tr><tr><td>Secondary Somatosensory</td><td>+/−  52</td><td>−28</td><td>21</td></tr><tr><td>Somatomotor</td><td>+/−  6</td><td>1</td><td>68</td></tr><tr><td>Temporal Pole</td><td>+/−  41</td><td>10</td><td>−32</td></tr><tr><td>Amygdala</td><td>+/−  22</td><td>−1</td><td>−22</td></tr><tr><td>Middle Temporal</td><td>+/−  60</td><td>−26</td><td>−5</td></tr><tr><td>Caudate</td><td>+/− 14</td><td>13</td><td>11</td></tr><tr><td>Middle Occipital</td><td>+/−  34</td><td>− 72</td><td>6</td></tr><tr><td>Cuneus</td><td>+/− 13</td><td>− 93</td><td>9</td></tr><tr><td>Hypothalamus</td><td>+/− 6</td><td>−6</td><td>−12</td></tr><tr><td>Lingual Gyrus</td><td>+/−  19</td><td>− 64</td><td>−11</td></tr><tr><td>Spinal Trigeminal Nucleus</td><td>+/− 6</td><td>− 39</td><td>− 45</td></tr><tr><td>Precuneus</td><td>+/−  6</td><td>− 58</td><td>46</td></tr><tr><td>Parieto-Occipital</td><td>+/−  51</td><td>−64</td><td>18</td></tr><tr><td>Supramarginal Gyrus</td><td>+/− 44</td><td>− 42</td><td>24</td></tr><tr><td>Precentral</td><td>+/− 44</td><td>−4</td><td>40</td></tr><tr><td>Middle Frontal</td><td>+/−  35</td><td>6</td><td>52</td></tr><tr><td>Pulvinar</td><td>+/− 20</td><td>−34</td><td>3</td></tr><tr><td>Fusiform Gyrus</td><td>+/− 51</td><td>− 59</td><td>−9</td></tr><tr><td>Superior Parietal</td><td>+/− 40</td><td>−52</td><td>− 49</td></tr><tr><td>Dorsal Pons</td><td>+/− 6</td><td>−36</td><td>−27</td></tr><tr><td>Cerebellum</td><td>+/− 46</td><td>− 53</td><td>−39</td></tr><tr><td>Periaqueductal Gray</td><td>−1</td><td>−26</td><td>−11</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>Tab3</table-id><table-label>Table 3</table-label><table-caption>Pre-treatment demographics, headache and migraine frequency, scores on ASC-12, MIDAS, BDI, and temperatures required to elicit moderate intensity pain. Medication overuse refers to participants who were using abortive medications more often than the thresholds defined for medication overuse by the ICHD-3 diagnostic criteria. Concurrent migraine preventive medication refers to the percentage of participants who were using migraine preventive medications in addition to erenumab. There were no differences in these pre-treatment values between participants who became erenumab responders vs. erenumab non-responders except that a larger proportion of participants who became erenumab responders were using concurrent migraine preventive medications. ASC-12 = Allodynia Symptom Checklist 12; MIDAS = Migraine Disability Assessment; BDI = Beck Depression Inventory</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab3"><label>Table 3</label><caption><p>Pre-treatment demographics, headache and migraine frequency, scores on ASC-12, MIDAS, BDI, and temperatures required to elicit moderate intensity pain. Medication overuse refers to participants who were using abortive medications more often than the thresholds defined for medication overuse by the ICHD-3 diagnostic criteria. Concurrent migraine preventive medication refers to the percentage of participants who were using migraine preventive medications in addition to erenumab. There were no differences in these pre-treatment values between participants who became erenumab responders vs. erenumab non-responders except that a larger proportion of participants who became erenumab responders were using concurrent migraine preventive medications. ASC-12 = Allodynia Symptom Checklist 12; MIDAS = Migraine Disability Assessment; BDI = Beck Depression Inventory</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>All Participants (<italic>n</italic> = 32)</th><th>Erenumab Responders (<italic>n</italic> = 18)</th><th>Erenumab Non-Responders (<italic>n</italic> = 14)</th><th><italic>p</italic>-value (responders vs. non-responders)</th></tr></thead><tbody><tr><td>Age, mean (SD)</td><td>40.3 (13)</td><td>41.9 (13)</td><td>38.3 (13)</td><td>0.45</td></tr><tr><td>Female, percentage</td><td>91%</td><td>89%</td><td>93%</td><td>0.99</td></tr><tr><td>Headache Day Frequency/ 28 days, mean (SD)</td><td>15.8 (4.4)</td><td>15.8 (4.8)</td><td>15.7 (3.9)</td><td>0.96</td></tr><tr><td>Migraine Day Frequency/ 28 days, mean (SD)</td><td>13.8 (4.7)</td><td>14.8 (5.1)</td><td>12.6 (4.2)</td><td>0.20</td></tr><tr><td>Years with Migraine, mean (SD)</td><td>21.9 (12.4)</td><td>22.6 (12.9)</td><td>20.8 (12.2)</td><td>0.70</td></tr><tr><td>Medication Overuse, percentage</td><td>59.4%</td><td>66.7%</td><td>50%</td><td>0.47</td></tr><tr><td>Concurrent Migraine Preventive Medication, percentage</td><td>31.3%</td><td>55.6%</td><td>0%</td><td>.001</td></tr><tr><td>ASC-12 scores, mean (SD)</td><td>4.7 (3.1)</td><td>4.5 (3.1)</td><td>4.9 (3.2)</td><td>0.70</td></tr><tr><td>Thermode Temperature Causing Moderate Pain, mean (SD), <sup>0</sup>C</td><td>45.8 (2.4)</td><td>46.0 (2.8)</td><td>45.6 (1.8)</td><td>0.63</td></tr><tr><td>MIDAS scores, mean (SD)</td><td>35.9 (27)</td><td>38 (31)</td><td>33 (21)</td><td>0.61</td></tr><tr><td>BDI scores, mean (SD)</td><td>5.8 (4.8)</td><td>5.6 (4.3)</td><td>6.1 (5.6)</td><td>0.80</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 3<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Pre-treatment demographics, headache and migraine frequency, scores on ASC-12, MIDAS, BDI, and temperatures required to elicit moderate intensity pain. Medication overuse refers to participants who were using abortive medications more often than the thresholds defined for medication overuse by the ICHD-3 diagnostic criteria. Concurrent migraine preventive medication refers to the percentage of participants who were using migraine preventive medications in addition to erenumab. There were no differences in these pre-treatment values between participants who became erenumab responders vs. erenumab non-responders except that a larger proportion of participants who became erenumab responders were using concurrent migraine preventive medications. ASC-12 = Allodynia Symptom Checklist 12; MIDAS = Migraine Disability Assessment; BDI = Beck Depression Inventory</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>All Participants (n = 32)</th><th>Erenumab Responders (n = 18)</th><th>Erenumab Non-Responders (n = 14)</th><th>p-value (responders vs. non-responders)</th></tr></thead><tbody><tr><td>Age, mean (SD)</td><td>40.3 (13)</td><td>41.9 (13)</td><td>38.3 (13)</td><td>0.45</td></tr><tr><td>Female, percentage</td><td>91%</td><td>89%</td><td>93%</td><td>0.99</td></tr><tr><td>Headache Day Frequency/ 28 days, mean (SD)</td><td>15.8 (4.4)</td><td>15.8 (4.8)</td><td>15.7 (3.9)</td><td>0.96</td></tr><tr><td>Migraine Day Frequency/ 28 days, mean (SD)</td><td>13.8 (4.7)</td><td>14.8 (5.1)</td><td>12.6 (4.2)</td><td>0.20</td></tr><tr><td>Years with Migraine, mean (SD)</td><td>21.9 (12.4)</td><td>22.6 (12.9)</td><td>20.8 (12.2)</td><td>0.70</td></tr><tr><td>Medication Overuse, percentage</td><td>59.4%</td><td>66.7%</td><td>50%</td><td>0.47</td></tr><tr><td>Concurrent Migraine Preventive Medication, percentage</td><td>31.3%</td><td>55.6%</td><td>0%</td><td>.001</td></tr><tr><td>ASC-12 scores, mean (SD)</td><td>4.7 (3.1)</td><td>4.5 (3.1)</td><td>4.9 (3.2)</td><td>0.70</td></tr><tr><td>Thermode Temperature Causing Moderate Pain, mean (SD), 0C</td><td>45.8 (2.4)</td><td>46.0 (2.8)</td><td>45.6 (1.8)</td><td>0.63</td></tr><tr><td>MIDAS scores, mean (SD)</td><td>35.9 (27)</td><td>38 (31)</td><td>33 (21)</td><td>0.61</td></tr><tr><td>BDI scores, mean (SD)</td><td>5.8 (4.8)</td><td>5.6 (4.3)</td><td>6.1 (5.6)</td><td>0.80</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>Tab4</table-id><table-label>Table 4</table-label><table-caption>Changes in headache frequency, migraine frequency, and ASC-12 scores. Change in headache and migraine frequency compares weeks 5–8 after the first erenumab treatment to the 4-week pre-treatment period. Change in ASC-12 scores compares those obtained during the research visit at 8 weeks after the first erenumab treatment to those collected just before the first treatment. ASC-12 = Allodynia Symptom Checklist 12</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab4"><label>Table 4</label><caption><p>Changes in headache frequency, migraine frequency, and ASC-12 scores. Change in headache and migraine frequency compares weeks 5–8 after the first erenumab treatment to the 4-week pre-treatment period. Change in ASC-12 scores compares those obtained during the research visit at 8 weeks after the first erenumab treatment to those collected just before the first treatment. ASC-12 = Allodynia Symptom Checklist 12</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>All Participants (<italic>n</italic> = 32)</th><th>Responders (<italic>n</italic> = 18)</th><th>Non-Responders (<italic>n</italic> = 14)</th><th>p-value (responders vs. non-responders)</th></tr></thead><tbody><tr><td>Change in Headache Day Frequency/ 28 days, mean</td><td>− 7.1</td><td>−10.1</td><td>− 3.4</td><td>&lt; 0.001</td></tr><tr><td>Change in Migraine Day Frequency/ 28 days, mean</td><td>− 6.9</td><td>− 10.3</td><td>−2.4</td><td>&lt; 0.001</td></tr><tr><td>Change in ASC-12 scores, mean</td><td>− 1.6</td><td>−3.4</td><td>0.8</td><td>&lt; 0.001</td></tr></tbody></table></table-wrap></original-table><transformed-table>Table 4<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Changes in headache frequency, migraine frequency, and ASC-12 scores. Change in headache and migraine frequency compares weeks 5–8 after the first erenumab treatment to the 4-week pre-treatment period. Change in ASC-12 scores compares those obtained during the research visit at 8 weeks after the first erenumab treatment to those collected just before the first treatment. ASC-12 = Allodynia Symptom Checklist 12</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>All Participants (n = 32)</th><th>Responders (n = 18)</th><th>Non-Responders (n = 14)</th><th>p-value (responders vs. non-responders)</th></tr></thead><tbody><tr><td>Change in Headache Day Frequency/ 28 days, mean</td><td>− 7.1</td><td>−10.1</td><td>− 3.4</td><td>&lt; 0.001</td></tr><tr><td>Change in Migraine Day Frequency/ 28 days, mean</td><td>− 6.9</td><td>− 10.3</td><td>−2.4</td><td>&lt; 0.001</td></tr><tr><td>Change in ASC-12 scores, mean</td><td>− 1.6</td><td>−3.4</td><td>0.8</td><td>&lt; 0.001</td></tr></tbody></table></div></transformed-table></extracted-table><extracted-table><table-id>Tab5</table-id><table-label>Table 5</table-label><table-caption>Regional network differences between erenumab responders and non-responders at 8 weeks after the first erenumab treatment. Shown for all uncorrected p-values of 0.05 or less. Numbers in parentheses are standard deviations. Inf = inferior; Lat = lateral</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab5"><label>Table 5</label><caption><p>Regional network differences between erenumab responders and non-responders at 8 weeks after the first erenumab treatment. Shown for all uncorrected <italic>p</italic>-values of 0.05 or less. Numbers in parentheses are standard deviations. Inf = inferior; Lat = lateral</p></caption><graphic position="anchor" xlink:href="10194_2022_1526_Tab5_HTML" id="MO7"/></table-wrap></original-table><transformed-table>Table 5<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Regional network differences between erenumab responders and non-responders at 8 weeks after the first erenumab treatment. Shown for all uncorrected p-values of 0.05 or less. Numbers in parentheses are standard deviations. Inf = inferior; Lat = lateral</div><div xmlns="http://www.w3.org/1999/xhtml"><a id="MO7"/><img src=""/></div></transformed-table></extracted-table><extracted-table><table-id>Tab6</table-id><table-label>Table 6</table-label><table-caption>ROI-to-ROI functional connectivity differences between erenumab responders and non-responders at 8 weeks after the first erenumab treatment. Results with uncorrected p-values of 0.005 or less are shown. Inf = inferior; lat = lateral; DLPFC = dorsolateral prefrontal cortex; VMPFC = ventromedial prefrontal cortex</table-caption><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab6"><label>Table 6</label><caption><p>ROI-to-ROI functional connectivity differences between erenumab responders and non-responders at 8 weeks after the first erenumab treatment. Results with uncorrected <italic>p</italic>-values of 0.005 or less are shown. Inf = inferior; lat = lateral; DLPFC = dorsolateral prefrontal cortex; VMPFC = ventromedial prefrontal cortex</p></caption><graphic position="anchor" xlink:href="10194_2022_1526_Tab6_HTML" id="MO8"/></table-wrap></original-table><transformed-table>Table 6<div xmlns="http://www.w3.org/1999/xhtml" class="caption">ROI-to-ROI functional connectivity differences between erenumab responders and non-responders at 8 weeks after the first erenumab treatment. Results with uncorrected p-values of 0.005 or less are shown. Inf = inferior; lat = lateral; DLPFC = dorsolateral prefrontal cortex; VMPFC = ventromedial prefrontal cortex</div><div xmlns="http://www.w3.org/1999/xhtml"><a id="MO8"/><img src=""/></div></transformed-table></extracted-table></extracted-tables-set>